In my opinion, splitting Amarin rights up amongst 3 big pharmas might yield the biggest return. Sell Europe to one pharma, north and South America to another and the ROW to another. They get V, the rights to once a day and the combo. Amarin splits the inventory with the new owners and remaining cash goes to shareholders.